Zogenix (NASDAQ:ZGNX) shareholders have had a roller coaster ride in 2014, with the share price climbing to almost $5 per share before cratering below $1.70. Tremendous controversy has swirled around Zohydro ER, an opioid painkiller that many fear could be abused.
The company received good news when Massachusetts Governor Deval Patrick's regulations to restrict the drug's usage were overturned by a federal court, and announced further good news that it may have a more tamper-resistant version of the drug out by 2015.
The big question: Has all the negativity been priced in already, or is this stock still one to avoid? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.